News & Updates

Show Multimedia Only
Canakinumab improves survival in advanced NSCLC

Canakinumab improves survival in advanced NSCLC

07 Oct 2023 byStephen Padilla

Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.

07 Oct 2023